Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Prepaid Assets: 2009-2024

Historic Prepaid Assets for Cytokinetics (CYTK) over the last 15 years, with Dec 2024 value amounting to $15.3 million.

  • Cytokinetics' Prepaid Assets rose 95.14% to $13.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.0 million, marking a year-over-year increase of 95.14%. This contributed to the annual value of $15.3 million for FY2024, which is 27.90% up from last year.
  • As of FY2024, Cytokinetics' Prepaid Assets stood at $15.3 million, which was up 27.90% from $11.9 million recorded in FY2023.
  • In the past 5 years, Cytokinetics' Prepaid Assets registered a high of $15.3 million during FY2024, and its lowest value of $5.7 million during FY2020.
  • In the last 3 years, Cytokinetics' Prepaid Assets had a median value of $12.5 million in 2022 and averaged $13.2 million.
  • In the last 5 years, Cytokinetics' Prepaid Assets skyrocketed by 112.77% in 2021 and then declined by 4.16% in 2023.
  • Cytokinetics' Prepaid Assets (Yearly) stood at $5.7 million in 2020, then soared by 112.77% to $12.2 million in 2021, then grew by 2.02% to $12.5 million in 2022, then decreased by 4.16% to $11.9 million in 2023, then rose by 27.90% to $15.3 million in 2024.